The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback